New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC ...

Recent research throws into question whether GLP-1 drugs increase the risk of certain types of thyroid cancer.

Ozempic and similar GLP-1 weight-loss medications are designed to be a lifelong treatment. But a new study finds the majority ...

Singer Michael Trotter Jr of The War and Treaty, chef Franklin Becker of “Top Chef Masters,” and a beauty salon owner ...

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC highlights ...

Medscape Medical News, February 05, 2025 Alert Ozempic Receives New Indications in Chronic Kidney Disease Semaglutide is now approved for reducing the risk for worsening kidney disease and ...

Carley is a writer, editor and social media professional. Before starting at Forbes Health, she wrote for Sleepopolis and interned at PBS and Nickelodeon. She's a certified sleep science coach and ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Chronic Kidney Disease (CKD) indicates prolonged kidney damage over three months, often undetectable until significant harm occurs. Key risk factors include diabetes, high blood pressure ...

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.